jeudi 27 février 2020

Onco Actu du 27 février 2020


1. BIOLOGIE



Structural framework for tumors also provides immune protection [Augusta University]











1.1 BIOLOGIE - GÉNOME



Breast cancer: altered chromosomes lead to treatment resistance [DKFZ]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



'Electronic nose' sniffs out condition that can lead to cancer [NHS Choices]










4.12 BIOPSIES LIQUIDES



Blood Test Can Predict Clinical Response to Immunotherapy in Metastatic Non-Small Cell Lung Cancer [Penn Medicine]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



Surveillance Imaging After Surgery Does Not Improve Outcomes for Patients with Glioblastoma [University of Missouri]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



MGI Deconstructs the Sequencer [Omics! Omics!]










China’s BGI says it can sequence a genome for just $100 [MIT Technology Review]











MGI Delivers the $100 Genome at AGBT Conference [GEN]











5. TRAITEMENTS



Genetic Impact of NeoAdj Breast Cancer Chemo [SWOG]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Targeting Stromal Cells May Help Overcome Treatment Resistance in Glioblastoma [Penn Medicine]











5.10 TRAITEMENTS - ESSAIS



Clinical trial sponsors have to disclose decade’s worth of unreleased data, federal judge rules [EndPoints]











Missing clinical trial data must be made public, federal judge says [Science]











5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Immune therapy reduces risk of recurrence in aggressive breast cancer [EurekAlert!]










5.2 PHARMA



FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer [Lilly]











European Medicines Agency accepts submission of GSK’s Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer [GSK]











5.2.1 PHARMA - PARTENARIATS



Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM Capital [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA approves neratinib for metastatic HER2-positive breast cancer [FDA]










5.4 TRAITEMENTS - ECONOMIE



NICE rejects Roche's new cancer med Polivy on lack of long-term evidence [Fierce Pharma]











Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma [NICE]











Polivy struck by NICE ‘no’ [Pharma Times]











6. LUTTE CONTRE LES CANCERS



Growing old with cancer [UICC]











6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



An Open Agenda: European Funder Approaches to Open Science [The Scholarly Kitchen]